Heart Eye Unveils AI-Driven Retinal Imaging System for Cardiovascular Risk Detection

Heart Eye Diagnostics Limited, a UK-based company, has announced the launch of Dr.Noon CVD, an advanced AI-powered retinal imaging system designed to detect and predict cardiovascular disease (CVD) risks. This noninvasive technology offers an alternative to traditional screening methods such as blood tests, CT scans, and carotid ultrasounds, making cardiovascular risk assessment more accessible and efficient.

AI-Powered Retinal Imaging: A New Era in CVD Risk Assessment

Dr.Noon CVD utilizes artificial intelligence (AI) algorithms to analyze ocular biomarkers, providing insights into an individual’s cardiovascular health. According to Heart Eye, the AI system has demonstrated predictive accuracy comparable to heart CT scans, but without the associated drawbacks such as radiation exposure, long wait times, and high costs.

The system is currently being developed further to assess other systemic health factors, including kidney function, using retinal biomarkers.

Global Validation and Scalability

Dr.Noon CVD’s deep-learning algorithm has been validated on a global cohort, ensuring high predictive performance. The system is designed to be cost-effective and scalable, allowing for broader accessibility to individuals who may not have access to conventional CVD screening methods.

“Traditional methods like heart CT scans come with drawbacks for mass screening, including high radiation doses, long wait times, and expensive costs. This technology helps lower healthcare costs by detecting potential issues early and preventing strokes and heart disease before they become serious,” said Husain Khaki, Director of Heart Eye.

Rapid Screening for Early Intervention

One of the key advantages of Dr.Noon CVD is its speed, with results available in just three minutes. This rapid turnaround time allows opticians, hospitals, and primary care providers to act quickly with preventative care strategies, improving patient outcomes.

“The fact that results are available in just three minutes is a game-changer,” said Khaki. “It enables faster diagnosis and intervention, significantly benefiting patients at risk of cardiovascular disease.”

Upcoming Live Demonstrations in the UK

Heart Eye will offer free cardiovascular disease risk retinal scans using Dr.Noon CVD at two upcoming industry events:

       • 100% Optical – March 1-3 at ExCeL, London

       • Optix Conference – March 17-19 at The Celtic Manor, Wales

These events will provide healthcare professionals with first-hand experience of this innovative AI-driven screening tool.

With Dr.Noon CVD, Heart Eye aims to redefine cardiovascular risk assessment, making it faster, more accessible, and highly accurate, ultimately improving patient care and reducing the burden of heart disease worldwide.